Doxorubicin hydrochloride 2 mg/ml solution for infusion
Sponsors
University College London, Takeda Development Center Americas Inc., Institut Gustave Roussy
Conditions
Advanced Classical Hodgkin LymphomaPatients with High Risk Neuroblastoma stage IA/IIA Hodgkin lymphoma
Phase 3
RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
RecruitingCTIS2022-500031-37-00
Start: 2024-04-08Target: 289Updated: 2025-06-23
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Active, not recruitingCTIS2023-506419-16-00
Start: 2013-01-08Target: 448Updated: 2025-12-15
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) “Randomized, international and multicentric phase 3 study that evaluates and compares 2 treatment strategies in 3 therapeutic phases (induction, high-dose chemotherapy and radiotherapy) for patients with high-risk neuroblastoma and introduces chemoimmunotherapy for patients with insufficient metastatic response after induction chemotherapy
RecruitingCTIS2024-514917-36-00
Start: 2024-11-21Target: 719Updated: 2025-01-17